ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 159 filers reported holding ESPERION THERAPEUTICS INC NE in Q1 2021. The put-call ratio across all filers is 3.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $9,862,000 | -24.1% | 379,326 | +8.6% | 0.01% | -42.9% |
| Q3 2020 | $12,987,000 | -29.6% | 349,403 | -2.8% | 0.01% | -36.4% |
| Q2 2020 | $18,444,000 | +83.7% | 359,464 | +12.9% | 0.02% | +29.4% |
| Q1 2020 | $10,038,000 | -48.5% | 318,352 | -2.6% | 0.02% | -26.1% |
| Q4 2019 | $19,487,000 | +93.2% | 326,798 | +18.8% | 0.02% | +53.3% |
| Q3 2019 | $10,087,000 | -20.3% | 275,153 | +1.1% | 0.02% | +50.0% |
| Q2 2019 | $12,658,000 | +15.2% | 272,097 | -0.6% | 0.01% | -33.3% |
| Q1 2019 | $10,989,000 | -12.8% | 273,677 | -0.1% | 0.02% | +25.0% |
| Q4 2018 | $12,607,000 | -17.2% | 274,061 | -20.2% | 0.01% | -40.0% |
| Q3 2018 | $15,232,000 | +21.1% | 343,294 | +7.0% | 0.02% | +11.1% |
| Q2 2018 | $12,573,000 | -41.0% | 320,815 | +8.9% | 0.02% | -47.1% |
| Q1 2018 | $21,318,000 | +35.8% | 294,730 | +23.6% | 0.03% | +41.7% |
| Q4 2017 | $15,695,000 | +64.9% | 238,384 | +25.5% | 0.02% | -20.0% |
| Q3 2017 | $9,517,000 | – | 189,899 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,679,835 | $99,609,000 | 22.32% |
| Bellevue Group AG | 5,465,715 | $203,160,000 | 2.81% |
| Rhenman & Partners Asset Management AB | 455,000 | $16,912,000 | 1.50% |
| Endurant Capital Management LP | 135,901 | $5,051,000 | 1.49% |
| Boxer Capital, LLC | 975,000 | $36,241,000 | 1.25% |
| DCF Advisers, LLC | 56,500 | $2,100,000 | 1.07% |
| Pentwater Capital Management LP | 2,169,022 | $80,623,000 | 1.04% |
| Nicholas Investment Partners, LP | 235,855 | $8,767,000 | 0.95% |
| Amia Capital LLP | 20,464 | $761,000 | 0.88% |
| HAMILTON LANE ADVISORS LLC | 46,181 | $1,717,000 | 0.83% |